MedTrace Logo

Effect of Quetiapine on Marijuana Withdrawal and Relapse

NCT00743366 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2017-08-18

Study results available
· View outcomes & findings →

Summary

The objective of this study is to investigate the interaction between marijuana and quetiapine, with the goal of using this information to improve marijuana treatment outcome.

Conditions

  • Marijuana Smoking

Interventions

DRUG

Marijuana

0,6.2% THC

DRUG

Quetiapine

200 mg/day

DRUG

Placebo oral capsule

Sponsors & Collaborators

  • Research Foundation for Mental Hygiene, Inc.

    collaborator OTHER

  • National Institute on Drug Abuse (NIDA)

    collaborator NIH

  • New York State Psychiatric Institute

    lead OTHER

Principal Investigators

  • Margaret Haney, Ph.D · New York State Psychiatric Institute

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
21 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-08-31
Primary Completion
2009-03-31
Completion
2009-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00743366 on ClinicalTrials.gov